Verification evidence is still being completed.
PDF / print export
Desentum
Espoo, Finland
- Verified lead
- Pekka Mattila
- Lead status
- STATUS: VERIFIED MARCH 2026
- Leadership verification
- CEO
- 2026 technical specialization
- Allergen Immunotherapy, Allergy Treatment, Clinical Development, and Biopharma
- Review cycle
- May 2026
- Full address
- Tekniikantie 14, 02150 Espoo, Finland
- Site coordinates
- Verification evidence is still being completed.
- Editorial review
- Memel Biotech editorial review
- Official leadership source
- Official Desentum contact page confirming the Espoo address.
- Editorial note
- Desentum is published because official company materials confirm current leadership, Espoo operating address, and a real allergen-immunotherapy platform.
Allergen Immunotherapy, Allergy Treatment, Clinical Development, and Biopharma
Official leadership disclosure, Official Espoo address disclosure, Clinical-stage therapeutics platform claim
Desentum is published because official company materials confirm current leadership, Espoo operating address, and a real allergen-immunotherapy platform.
Review coverage
Leadership
Facility
Certifications
Capabilities
Partners
Sources
Quality
Editorial verificationMemel Biotech directory review sign-off
Report generated02 Jun 2026, 01:40
Company profile · Espoo, Finland
Desentum
Allergen Immunotherapy, Allergy Treatment, Clinical Development, and Biopharma · Clinical-stage therapeutics platform
Desentum runs allergen immunotherapy development, clinical program execution, and biopharma platform development in Espoo, Finland.
- Lead
- Pekka Mattila (verified ↗)
- Address
- Tekniikantie 14, 02150 Espoo, Finland (source ↗)
- Compliance
- Not yet on record
- Last reviewed
- 22 Mar 2026 (2mo ago)
- Scale
- Clinical-stage therapeutics platform
- Capabilities
- Allergen Immunotherapy Development · Clinical Program Execution · Biopharma Platform Development
- Founded
- 2009
- Headcount
- 1-10
- Company page (open ↗)
Clinical profileSTATUS: VERIFIED MARCH 2026
Pekka Mattila
CEO
Full addressTekniikantie 14, 02150 Espoo, Finland
Site coordinatesVerification evidence is still being completed.
Review cycleMay 2026
Clinical-stage therapeutics platform
Espoo, Finland. Allergen Immunotherapy, Allergy Treatment, Clinical Development, and Biopharma. Review completed on 22 Mar 2026.
Finnish corporate and clinical-development oversight
Official leadership disclosure, Official Espoo address disclosure, Clinical-stage therapeutics platform claim
Allergen Immunotherapy, Allergy Treatment, Clinical Development, and Biopharma
Desentum is published because official company materials confirm current leadership, Espoo operating address, and a real allergen-immunotherapy platform.
Editorial note
Desentum is published because official company materials confirm current leadership, Espoo operating address, and a real allergen-immunotherapy platform.
FULL TRUST REVIEW COMPLETE
Shown only when all seven trust checks are fully mapped in the directory.
Current review cycleMarch 2026
Capabilities
Core capabilities
Primary declared technical activities and areas of operating focus.
Allergen Immunotherapy Development
Clinical Program Execution
Biopharma Platform Development
Verification source dossier
Verification source dossier
Official source set used to support leadership, physical-site, certification, and watch-note evidence.
Infrastructure
Declared infrastructure
Clinical development workflow
Allergy-treatment R&D systems
Program management infrastructure
Regulatory posture
Quality system coverage
GMP / GLP / ISO-13485 / FDA-Inspected are global quality-system standards. "Verified active" means the directory confirmed the certification is current; "Review in progress" means the cert status is currently being re-verified.
- GMP
- REVIEW IN PROGRESS 2026
- GLP
- REVIEW IN PROGRESS 2026
- ISO-13485
- REVIEW IN PROGRESS 2026
- FDA-Inspected
- REVIEW IN PROGRESS 2026
Verification history
Verification history
22 Mar 2026: Executive identity confirmed via official management disclosure.
22 Mar 2026: Full trust review completed.
FAQ
Frequently asked questions
- Where is Desentum located?
- Desentum operates from Tekniikantie 14, 02150 Espoo, Finland, Espoo, Finland.
- Who runs Desentum?
- Desentum is led by Pekka Mattila, CEO. Verified 22 Mar 2026.
- What does Desentum do?
- Desentum runs allergen immunotherapy development, clinical program execution, and biopharma platform development in Espoo, Finland. Core capabilities: Allergen Immunotherapy Development, Clinical Program Execution, Biopharma Platform Development.
Editorial context
Related technical briefs
Briefs that name Espoo as a covered market or city.